"We engaged Bill to drive the transition of a key program from late lead optimization to candidate selection, and into IND-enabling studies. Bill provided a gap analysis and identified critical-path studies that would ensure the program met big pharma in-licensing criteria for preclinical assets. Bill effectively managed those studies, prepared the data package, and presented the results, greatly contributing to our success. "
Mark Velleca, M.D., SVP and Founder, Cellular Genomics Inc
“I worked with Bill at Memory Pharmaceuticals when I was Sr. VP and President of Research. Bill established a high-quality, actively engaged preclinical development group that supported early and late-stage discovery and development projects. He is broadly knowledgeable and competent in bioanalytical assays, excellent to work with and has good management as well as presentation skills. I recommend him highly and without hesitation.”
James Barrett, President Research, Memory Pharmaceuticals
“I hired Bill as a consultant to help with preclinical development of several antibodies and proteins. His knowledge of pharmacokinetics, metabolism and toxicology is extensive. He has provided significant input into development of numerous products over his career.”
Mary Taylor, Ph.D., SVP, Curagen Corp
“A mutual colleague enthusiastically recommended in 2010 that I hire Dr. Bill Brubaker into the Orphan and Genetic Diseases Unit at Pfizer. His enthusiasm for Bill's candidacy was well-founded. Bill has a uniquely deep and broadly integrated set of experiences in all areas of preclinical development and translational research. Bill is particularly effective in bridging communication and interpretation of data across other research groups such as pharmacokinetics, distribution, metabolism, toxicology, medicinal chemistry, and pharmacodynamics. Bill provided comprehensive and insightful evaluations of outside therapeutic assets for potential acquisition or in-licensing. Additionally he had the lead responsibility for two key project teams working on treatments for orphan indications, functioning extremely well as the senior leader with matrixed team members. I enthusiastically recommend Bill for your serious consideration without reservation.”
Ed Mascioli, M.D., VP and CSO, Pfizer